| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Aktis Oncology is a clinical-stage oncology company engaged in the research, development, and commercialization of targeted radiopharmaceuticals to treat solid tumor cancers. Its lead candidate, [225Ac]Ac-AKY-1189, is a miniprotein radioconjugate in a Phase 1b trial for Nectin-4-expressing solid tumors, including urothelial, breast, lung, colorectal, and cervical cancers. A second candidate, [225Ac]Ac-AKY-2519, targets B7-H3-expressing tumors. The company has collaboration agreements with Protein Innovation, TRIUMF Innovations, and Eli Lilly.
| Market Cap | — | Trading Days | 2446 |
| 52W High | 34.19 |
| 52W Low | 0.00 |
| % Off High | −32.82% |
| YTD | 1531233.33% | 1Y | 22969900.00% |
| 3Y | 861.09% | 5Y | 142.56% |
| 10Y | 484.48% | Since incept. (ann.) | 25.66% |
| Ann. Volatility (1Y) | 2025185.57% | Ann. Volatility (3Y) | 1045553.08% |
| Sharpe (1Y) | 1.36 | Sharpe (3Y) | 0.70 |
| Max Drawdown (1Y) | −32.19% | Max Drawdown (3Y) | −100.00% |
| Beta (3Y, vs SPY) | 15142.70 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $124.46B | 32.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.32B | 16.8 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.88B | 26.2 |
